Objective To observe the clinical effect of monosialotetrahexosyl ganglioside sodium injection (GM1) on spastic cerebral palsy. Methods 98 children with spastic cerebral palsy were randomly divided into control group (n=50) and treatment group (n=48). Both groups received Bobath approach, and the treatment group received GM1 in addition. They were assessed with Functional Independence Measure for Children (WeeFIM), Gross Motor Function Measure (GMFM) and Gesell Development Schedule (GDS) before and after 90 days of treatment. Results The scores of WeeFIM, all the dimensions of GMFM and the gross motor, fine motor, personal-social and adaption of the GDS improved in both groups after treatment (P<0.05), and improved more in the treatment group than in the control group (P< 0.05). Conclusion GM1 may further improve the recovery of function for children with spastic cerebral palsy.

ObjectiveTo investigate the changes in serum soluble complement receptor type 1 (sCR1) at 3 and 6 months after antiviral therapy with telbivudine in patients with chronic hepatitis B (CHB) or liver cirrhosis and the influence of telbivudine on serum sCR1 level. MethodsA total of 57 patients with HBeAg-positive CHB or liver cirrhosis were enrolled and given the antiviral therapy with telbivudine. Venous blood was collected before treatment and at 3 and 6 months after treatment, and enzyme-linked immunosorbent assay was used to measure serum sCR1 level. The paired t-test was used for comparison within one group. ResultsAt 3 and 6 months after the antiviral treatment with telbivudine, the serum sCR1 level changed significantly compared with corresponding baseline values (t=4.864 and 6.238, both P＜0.05). The patients with CHB or liver cirrhosis showed significant changes in the serum sCR1 level at 3 and 6 months after treatment compared with corresponding baseline values (t=3425,5468,4047,7378 all P＜0.05). The patients with CHB had a lower serum sCR1 level at baseline and at 3 and 6 months after treatment than those with liver cirrhosis, but the serum sCR1 level at each time point showed no significant differences between the two groups (all P＞005). ConclusionIn patients with HBeAg-positive CHB or liver cirrhosis, serum sCR1 level is reduced significantly after antiviral therapy with telbivudine.